TY - JOUR
T1 - Immune checkpoints in targeted-immunotherapy of pancreatic cancer
T2 - New hope for clinical development
AU - Kiaie, Seyed Hossein
AU - Sanaei, Mohammad Javad
AU - Heshmati, Masoud
AU - Asadzadeh, Zahra
AU - Azimi, Iman
AU - Hadidi, Saleh
AU - Jafari, Reza
AU - Baradaran, Behzad
N1 - Publisher Copyright:
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
PY - 2021/5
Y1 - 2021/5
N2 - Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.
AB - Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.
KW - Clinical development
KW - Immune checkpoint
KW - Immunotherapy
KW - Pancreatic cancer
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85104107025&partnerID=8YFLogxK
U2 - 10.1016/j.apsb.2020.12.011
DO - 10.1016/j.apsb.2020.12.011
M3 - Review Article
C2 - 34094821
AN - SCOPUS:85104107025
SN - 2211-3835
VL - 11
SP - 1083
EP - 1097
JO - Acta Pharmaceutica Sinica B
JF - Acta Pharmaceutica Sinica B
IS - 5
ER -
